During a median follow-up of 2.41 years, 193 deaths occurred and 254 patients underwent liver transplantation. In patients with transferrin < 180 mg/dL, 3-month, 1-year and 5-year transplant-free survival estimates were significantly lower (91.7%, 79.0% and 30.5%) when compared with the group of patients with transferrin ≥ 180 mg/dL (98.9%, 95.5% and 68.0%, P < .001). Transferrin predicted transplant-free survival independently of MELD-Na and C-reactive protein (CRP) in multivariable regression analysis including all patients. When patients with alcoholic or non-alcoholic fatty liver disease were excluded, transferrin was in addition an albumin-independent predictor of transplant-free survival.
The analysis of the data showed that despite the progress of modern hepatology, the presence of HH is associated with poor prognosis and high mortality. Most patients suffering from it are candidates for orthotopic liver transplantation. I